中等度から重度の乾癬を有する成人患者を対象とした、セジロガント（ABBV-157）の有害事象および疾患活動性を評価する研究

基本情報

NCT ID

NCT05044234

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

156

治験依頼者名

AbbVie

概要

Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques. This study assessed how safe and effective cedirogant (ABBV-157) was compared to placebo in adult participants with moderate to severe psoriasis. Efficacy and safety-related measurements assessed disease activity in participants with plaque psoriasis. Cedirogant (ABBV-157) is an investigational drug being developed for the treatment of chronic plaque psoriasis. Participants were put into 1 of 4 groups, called treatment arms and each group received a different treatment. There was a 1 in 4 chance that participants were assigned to placebo. Participants received oral daily doses of cedirogant or placebo capsules for 16 weeks. There may have been a higher burden for participants in this study compared to usual standard of care. Participants attended regular visits per routine clinical practice. The effect of the treatment was checked by medical assessments, checking for side effects, and questionnaires.

対象疾患

介入

依頼者（Sponsor）

実施施設 (10)